Whole genome, ppm-level minimal residual disease detection
Discover what other tests may miss with unparalleled sensitivity and whole genome precision
Ultra-sensitive
limit of detection as low as 2ppm (LOD95)
Panel-free
leveraging Inocras’s proprietary cancer whole genome approach
Efficient workflow
enhancing cost-effectiveness and fast turnaround time
More data
generated per assay monitoring WGS ctDNA longitudinally
MRDVision is a whole-genome based, panel-free, tumor-informed liquid biopsy platform designed to detect minimum residual disease (MRD) from circulating tumor DNA (ctDNA), at a limit of detection as low as 2ppm.
Unlike existing MRD methods that rely on creating panels with a limited number of genes for each patient, MRDVision’s whole genome-based approach identifies and tracks genetic markers across the entire genome in every test, reducing the likelihood of missing mutations and recurrence.
Merging two advanced technologies: Experience a platform designed to maximize tumor signal while minimizing noise
Maximized signal powered by CancerVision, a whole genome cancer profiling platform, offering highly sensitive mutation detection (> 99% sensitivity for SNV and indel), and capturing copy number variations, structural variations, and mutations in non-coding areas with high precision.
Minimized noise powered by Ultima Genomics’ ppmSeq™ technology, enabling the detection of rare single nucleotide variants at the genome-wide scale with high sensitivity and low background error rates.
WGS Baseline
Tumor-normal paired whole genome cancer profiling
CancerVision delivers whole genome cancer profiling, creating individualized WGS tumor somatic signatures as a baseline for each patient.
Specimen requirements: 10 FFPE from curls or slides, with an H&E stained slide for reference and 10mL peripheral blood, or previously extracted DNA from a CLIA certified laboratory.
Turn around time: 2 weeks from receipt of samples.
ctDNA Monitoring
Comparing WGS baseline vs. WGS data in ctDNA
MRDVision then utilizes this personalized WGS baseline to detect tumor DNA fraction by analyzing WGS data from ctDNA.
Specimen requirements: 2 Streck tubes of peripheral blood, 10mL each.
Turn around time: 2 weeks from receipt of samples.
See what others miss with ultra-high sensitivity
| Key features | MRDVision | Widely adopted MRD products |
|---|---|---|
| Product concept | Tumor-informed | Tumor-informed |
| Genome coverage | Baseline: TE-WGS (CancerVision) ctDNA: WGS | Baseline: WES or WGS-based ctDNA: Personalized or fixed panel with limited number of variants |
| Limit of detection | 0.0001% (1 ppm) LOD95: as low as 2 ppm | Mostly 0.01% - 0.001% market-wide |
| Deliverable | WGS ctDNA monitoring report + TE-WGS cancer profiling data (CancerVision) | ctDNA monitoring report |
Ultra-high sensitivity at various tumor burden levels
LOD95 results across three cell lines:
- 2 ppm from NCI-H2126
117,676 SNV out of 169,079 somatic mutations - 5 ppm from HCC1395
38,829 SNV out of 67,191 somatic mutations - 15 ppm from HCC2218
23,494 SNV out of 51,350 somatic mutations
For biopharma
Accelerate your clinical development with MRDVision
-
Validate novel, predictive biomarkers, using comprehensive genomic data from MRD test
-
Stratify and enrich high risk patient subgroups who are most likely to benefit from novel therapies, driving more precise study design
-
Accelerate a clinical trial timeline using MRD as a surrogate marker to track early treatment response
-
Detect early signals on molecular changes to inform treatment success
For cancer researchers
Unlock the full potential of your cancer research
-
Discover novel biomarkers and identify molecular subtypes in cancer
-
Exploring the therapeutic impact at a molecular level, detect resistance mechanisms, and monitor tumor evolution over time
-
Advance liquid biopsy research with ctDNA WGS to pioneer new approaches in non-invasive diagnostics, tracking genetic alterations with high sensitivity
-
Scale your research with our competitively priced MRD assay to expand your research capabilities – without compromising on precision or scope
MRD resources
Submit a request
Thank you for your interest in partnering with us to advance your genomic research. Please fill out and submit this inquiry form and we will get in touch with you within 48 hours to address your project needs. We look forward to working with you.